---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-008054"
form_type: "8-K"
ticker: "PASG"
cik: "0001787297"
company_name: "Passage BIO, Inc."
filed_at: "2024-05-14T23:59:59+00:00"
generated_at: "2026-06-02T01:04:28.014987+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Passage Bio Q1 net loss $16.7M, cash $104.5M; PBFT02 shows sustained CSF PGRN in 2 patients

## Summary
- Net loss of $16.7M ($0.30/shr) vs $34.3M a year ago; cash $104.5M, runway through Q4 2025.
- Dose 1 PBFT02 elevated CSF progranulin (21.7–27.3 ng/mL) at 6 months in 2 FTD-GRN patients.
- Completed dosing Cohort 1 (n=5) in upliFT-D trial; 6-month safety/biomarker data due 2H 2024.
- Plan to initiate Cohort 2 dosing in 1H 2024; FDA feedback sought for FTD-C9orf72 indication.
- Raised $8.7M net under ATM facility in Q1 2024; R&D expenses $11.5M, G&A $6.5M.

## SEC filing metadata
- accession: 0001558370-24-008054
- form_type: 8-K
- ticker: PASG
- cik: 0001787297
- company_name: Passage BIO, Inc.
- filed_at: 2024-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787297/000155837024008054/0001558370-24-008054-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787297/000155837024008054/pasg-20240514x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-008054
- JSON: https://secwatch.observer/filing/0001558370-24-008054.json
- Plain text: https://secwatch.observer/filing/0001558370-24-008054.txt

## Key facts
- Earnings Releases
  Passage BIO, Inc. reported first quarter ended March 31, 2024 results: net income Net loss was $16.7 million, or $0.30 per basic and diluted share.
  - Period: first quarter ended March 31, 2024
  - Net income: Net loss was $16.7 million, or $0.30 per basic and diluted share
  - Result: reported results
  source text: Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today reported financial results for the first quarter ended March 31, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1787297/000155837024008054/0001558370-24-008054-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.